Key Documents
Amreen Husain, MD
- Associate Professor - Med Center Line, Obstetrics & Gynecology
- Member, Cancer Center
Contact Information
- Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr Clinic C Gynecologic Oncology Clinic Stanford, CA 94305 Telephone Work (650) 498-6000 Fax (650) 723-7448
- Academic Offices
Personal Information Email amreen.husain@stanford.eduAdministrative Contact Patient Appointment Tel Work 650-498-6000Not for medical emergencies or patient use
Clinical Focus
- Cervix Cancer
- Cervix Cancer - Gynecologic Oncology
- Endometrial Cancer
- Endometrial Cancer - Gynecologic Oncology
- Fallopian Tube
- Fallopian Tube - Gynecologic Oncology
- Female & Gynecologic Cancers
- Germ Cell Tumors
- Germ Cell Tumors - Gynecologic Oncology
- Gestational Trophoblastic Disease
- Gestational Trophoblastic Disease - Gynecologic Oncology
- Gynecologic Cancers
- Gynecologic Cancers - Gynecologic Oncology
- Gynecologic Cancers - Medical Oncology
- Gynecologic Oncology
- Gynecology
- Melanoma
- Melanoma - Gynecologic Oncology
- Ovarian Cancer
- Ovarian Cancer - Gynecologic Oncology
- Sarcomas - Soft Tissue
- Urethral Cancer
- Urethral Cancer - Gynecologic Oncology
- Uterine Cancer
- Uterine Cancer - Gynecologic Oncology
- Vaginal Cancer
- Vaginal Cancer - Gynecologic Oncology
Department
- Cancer > Gynecologic Cancer
Professional Education
- Board Certification: Gynecologic Oncology, American Board of Obstetrics and Gynecology (2003)
- Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (2002)
- Memorial Sloan-Kettering Cancer Center (2000) NY USA
- New York Hospital (1995) NY
- New York Hospital (1992) NY
- New York Medical College (1991) NY
Community & International Work
- Eritrean Womens' Project, Eritrea More »
Web Site Links
Clinical Trials
- Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Recruiting
- AZD6244 in Treating Woman With Recurrent Low-Grade Ovarian Cancer Recruiting
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Recruiting
- Collecting Tumor Samples From Patients With Gynecological Tumors Recruiting
- Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Recruiting
- Second Curettage in Treating Patients With Persistent Non-Metastatic Gestational Trophoblastic Tumor Recruiting
- Temsirolimus With or Without Megestrol and Tamoxifen in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Recruiting
- Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Recruiting
- A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS) Recruiting
- Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer Recruiting
- Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites Recruiting
- Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer No longer recruiting
- Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer No longer recruiting
- Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer No longer recruiting
- Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer No longer recruiting
- Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Suspended
- Clinical Trial for Ovarian Cancer (OvaRex®) Terminated
- Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA) No longer recruiting
- Safety and Efficacy Study of the Trifunctional Antibody Catumaxomab to Treat Ovarian Cancer in Women After a Complete Response to Chemotherapy Completed
Publications
- Gynecol Oncol. 2007; (1): 194-8
- Obstet Gynecol. 2007; (1): 12-9
- Obstet Gynecol. 2007; (6): 1342-50
- Gynecol Oncol. 2007; (2): 396-400
- Gynecol Oncol. 2007; (1): 177-80
- Int J Radiat Oncol Biol Phys. 2007; (2): 504-11
- J Womens Health (Larchmt). 2007; (2): 281-2
- Gynecol Oncol. 2007; (3): 641-9
- Br J Cancer. 2006; (10): 1314-20
- Cancer. 2006; (8): 1823-30
- Gynecol Oncol. 2006; (3): 1095-9
- Gynecol Oncol. 2006; (3): 919-23
- Gynecol Oncol. 2006; (2): 679-83
- Gynecol Oncol. 2006; (1): 190-4
- Gynecol Oncol. 2006; (3): 508-12
- Obstet Gynecol. 2006; (2 Pt 1): 329-35
- Obstet Gynecol. 2006; (3 Pt 1): 521-8
- Int J Radiat Oncol Biol Phys. 2005; (3): 839-44
- Int J Radiat Oncol Biol Phys. 2005; (4): 1114-21
- J Womens Health (Larchmt). 2005; (9): 839-44
- Gynecol Oncol. 2004; (1): 107-11
- Gynecol Oncol. 2001; (1): 44-7